Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
Tijdschrift voor Geneeskunde from Leuven, company number BE0410801631, closed financial year 2025 with a result of € -121,534 after tax. For that financial year Tijdschrift voor Geneeskunde recorded revenue of € 154,659 and equity of € 791,357. Compared with financial year 2024, the result moved from € -192,323 to € -121,534. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.
€ 791,357
▼ 13% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -121,534
▲ 37 % less loss than in 2024
Profit after tax over the fiscal year.
€ 50,967
▼ 48% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
1.4
▼ 1.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 93,619
▼ 51% vs 2024
€ 66,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 16,335
▲ 84% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 16,016
▼ 29% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 206,115 | € 203,048 | € 175,825 | € 154,659 | ▼ 12% |
| Gross margin | € 7,566 | € 29,473 | € -1,322 | € -10,595 | ▼ € 9,272 |
| Profit after taxes | € -232,635 | € -129,027 | € -192,323 | € -121,534 | ▲ € 70,789 |
| Equity | € 1,234,241 | € 1,105,214 | € 912,891 | € 791,357 | ▼ 13% |
| Total debts | € 132,783 | € 126,683 | € 108,781 | € 103,433 | ▼ 5% |
| Cash | € 109,080 | € 275,500 | € 98,678 | € 50,967 | ▼ 48% |
| Land & buildings | € 236,326 | € 224,345 | € 211,634 | € 200,383 | ▼ 5% |
| Retained profit | € -1,703,270 | € -1,832,297 | € -2,024,620 | € -2,146,154 | ▼ € 121,534 |
| Balance sheet total | € 1,367,024 | € 1,231,897 | € 1,021,672 | € 894,790 | ▼ 12% |
| Employees (FTE) | 2.5 | 2.6 | 2.7 | 1.4 | ▼ 1.3 |
Key figures of Tijdschrift voor Geneeskunde, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Tijdschrift voor Geneeskunde?
What happened at Tijdschrift voor Geneeskunde in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 121,534. Source: NBB ↗
- Patrick Lacor became a director. NBB
- Anne-Marie De Cock became a director. NBB
- Dirk Van Raemdonck became a director. NBB
- New establishment in Leuven. KBO
- Jan Heyrman became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 232,635 loss in 2022 to € 121,534 loss in 2025.
On average € 11,300 of value added per employee in 2023.
A new publication or filing at Tijdschrift voor Geneeskunde? We notify you, reason included.
Follow Tijdschrift voor GeneeskundeDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Tijdschrift voor Geneeskunde are Jan Heyrman, Patrick Lacor, Anne-Marie De Cock and Dirk Van Raemdonck. Anne-Marie De Cock is also behind DOKTER A.-M DE COCK. Dirk Van Raemdonck is also behind PROF. VAN RAEMDONCK CONSULTANCY.
Directors
According to the 2025 annual accounts
Jan Heyrman
Director
since 2016
Patrick Lacor
Director
since 2022
since 2022
since 2022
Establishments
Establishment units
Physical locations of this company
Celestijnenlaan 39 box 1
3001 Leuven
Celestijnenlaan 39
3001 Leuven
Active since 1 January 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Microsoft 365
Hosting
AS-UNIXSOLUTIONS Unix-Solutions Network, BE
Domain
Domain
tvgg.be
Registered
2020-06-15
Website info
Features
Security
Details
- Company number
- 0410.801.631
- VAT number
- BE 0410.801.631
- Registered office
- Celestijnenlaan 39 bus 1, 3001 Leuven
- Names & denominations
- Tijdschrift voor Geneeskunde
- Enterprise type
- Rechtspersoon
- Legal form
- Non-profit association
- Legal situation
- Normale toestand
- Start date
- 4 June 1962
- Peppol
- Active · Active since 5 Sept 2025
- Contact
- tvgg.be
- Activities · NACE
Uitgeven van tijdschriften
Uitgeverijen van tijdschriften